Abstract:Dermatologic TherapyVolume 35, Issue 11 e15781 LETTER Successful treatment of secukinumab-resistant palmoplantar pustulosis by Dupilumab: A case report Yu-Xin Zheng, Yu-Xin Zheng Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorMin Zheng, Min Zheng Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorSui-Qing Cai, Corresponding Author Sui-Qing Cai [email protected] Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China Correspondence Sui-Qing Cai, Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China. Email: [email protected]Search for more papers by this author Yu-Xin Zheng, Yu-Xin Zheng Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorMin Zheng, Min Zheng Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorSui-Qing Cai, Corresponding Author Sui-Qing Cai [email protected] Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China Correspondence Sui-Qing Cai, Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China. Email: [email protected]Search for more papers by this author First published: 20 August 2022 https://doi.org/10.1111/dth.15781 Funding information: This study was funded by the grant from the National Natural Science Foundation of China (NFSC) (82073426). Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Misiak-Galazka M, Zozula J, Rudnicka L. Palmoplantar Pustulosis: recent advances in Etiopathogenesis and emerging treatments. Am J Clin Dermatol. 2020; 21(3): 355-370. 2Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017; 389(10086): 2287-2303. 3Mrowietz U, Bachelez H, Burden AD, et al. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: results of the 2PRECISE study. J Am Acad Dermatol. 2019; 80(5): 1344-1352. 4Avallone G, Cariti C, Dapavo P, et al. Real-life comparison between secukinumab and ixekizumab in the treatment of pustular and erythrodermic psoriasis. J Eur Acad Dermatol Venereol. 2022; 36(7):e574-e576. 5Brumfiel CM, Patel MH, Zirwas MJ. Development of psoriasis during treatment with dupilumab: a systematic review. J Am Acad Dermatol. 2021; 86(3): 708-709. 6Russo F, Provvidenziale L, Bruzziches F, et al. Psoriasis-like eruption triggered by Dupilumab therapy. Dermatitis. 2021; 32(6): e147-e148. 7Safa G, Paumier V. Psoriasis induced by dupilumab therapy. Clin Exp Dermatol. 2019; 44(3): e49-e50. 8McCluskey D, Benzian-Olsson N, Mahil SK, et al. Single-cell analysis implicates Th17 to Th2 cell plasticity in the pathogenesis of palmoplantar pustulosis. J Allergy Clin Immunol. 2022;S0091-6749(22)00624-8. Volume35, Issue11November 2022e15781 ReferencesRelatedInformation

Case report: Successful treatment with biologics in a pediatric patient with a severe inflammatory skin disease and novel CARD14 mutation

A novel variant with a severe phenotype in CARD14-associated papulosquamous eruption successfully treated with ixekizumab

Severe atypical juvenile pityriasis rubra pilaris diagnosed in adulthood with a dramatic improvement with ustekinumab

CARD14 Missense Variant Underlying CARD14-Associated Papulosquamous Eruption with Beneficial Response to Secukinumab.

Case report: Clinical and histopathological characteristics of psoriasiform erythema and de novo IL-17A cytokines expression on lesioned skin in atopic dermatitis children treated with dupilumab

Case report: Infantile generalized pustular psoriasis with IL36RN and CARD14 gene mutations

CARD14 signalosome formation is associated with its endosomal relocation and mTORC1-induced keratinocyte proliferation

Case report: Treatment of psoriasiform dermatitis in patients with malignancy

Effectiveness and Safety of Etanercept in Paediatric Patients with Plaque-Type Psoriasis: Real-World Evidence

Successful Treatment of Secukinumab-Resistant Palmoplantar Pustulosis by Dupilumab: A Case Report.

Acute generalized exanthematous pustulosis caused by hydroxychloroquine in a patient with rheumatoid arthritis and CARD14 mutation: Case report

Evolving Landscape of Biologic Therapy for Pediatric Psoriasis

Biologics for psoriasis patients under 18 years of age: Real-world evidence from the Chinese psoriasis real world evidence research group

Case Report: Coexistence of bullous pemphigoid and psoriasis: Therapeutic challenge and IL17A-targeted parallel treatment strategy

Erythrodermic psoriasis and palmoplantar hyperkeratosis successfully treated with secukinumab: a case report

BI05 Successful treatment with upadacitinib for severe atopic dermatitis in a patient with primary immunodeficiency (CARD11)

727 - Case series on real-world experience of biologics in the management of atopic dermatitis in paediatric population at King’s College Hospital, London

A Case of Paradoxical Reactions to Biologic Therapy for Psoriasis

A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab

Case report: Psoriasiform eczema with immune-mediated comorbidities treated with upadacitinib

Emerging Role of Biologic Drugs Targeting IL-17 and IL-23: Pityriasis Rubra Pilaris